A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

← catalyst calendar

NCT04626635 · readout in 86 d

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.

Phase

Phase 1/2

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

548actual

Sites

Countries

France, Israel, Netherlands +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2020-12-21

actual

When the study began enrolling

Primary completion

2026-11-13

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-03-05

estimated

The whole study's end, after follow-up

First posted

2020-11-12

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-02

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Advanced Solid Tumors

Interventions

Drug: REGN7075 — also filed as marlotamig
Drug: Cemiplimab — also filed as REGN2810, Libtayo
Drug: Platinum-based doublet chemotherapy
Drug: Bevacizumab
Drug: Trifluridine-tipiracil

Primary outcomes

what the primary-completion date above is the date OF

The incidence of Dose-Limiting Toxicities (DLTs) during the DLT period

measured Up to 6 weeks

Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)

measured Approximately 90 days from last dose; up to 5 years

Incidence and severity of Adverse Events of Special Interest (AESIs)

measured Approximately 90 days from last dose; up to 5 years

Incidence and severity of Serious Adverse Events (SAEs)

measured Approximately 90 days from last dose; up to 5 years

Incidence and severity of grade ≥3 laboratory abnormalities

measured Approximately 90 days from last dose; up to 5 years

Objective Response Rate (ORR)

measured Up to 5 years

Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed